[Gastric neuroendocrine neoplasms: update on endoscopic and surgical management].

Elisabeth Maurer, Ulrike Denzer, Detlef K Bartsch

Abstract readEnglish AbstractReview

In one paragraph

Review in Chirurgie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Elisabeth MaurerKlinik für Viszeral‑, Thorax- und Gefäßchirurgie, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Baldingerstr., 35043, Marburg, Deutschland. maurere@med.uni-marburg.de.

Ulrike DenzerSektion Endoskopie, Klinik für Gastroenterologie, Endokrinologie, Stoffwechsel und klinische Infektiologie, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Marburg, Deutschland.

Detlef K BartschKlinik für Viszeral‑, Thorax- und Gefäßchirurgie, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Baldingerstr., 35043, Marburg, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For type I gastric neuroendocrine neoplasms (gNEN) larger than 1 cm endoscopic resection should be performed, whereas for tumors larger than 2 cm surgical resection should be carried out. Tumors between 1 and 2 cm in size are generally resected endoscopically following endosonography; however, surgery should be considered in the presence of risk factors such as G2/3 tumors, infiltration of the muscularis propria and vascular invasion. Type II gNENs are treated endoscopically or surgically in the same manner as type I tumors. It is essential to consider treatment of the underlying hypergastrinemia caused by duodenal wall gastrinomas as well as treatment of any potentially concurrent primary hyperparathyroidism (pHPT). For type III gNENs surgical resection is generally recommended. In selected patients with very rare, small (< 1 cm) G1 tumors, endoscopic resection can be appropriate.

Indexed as

GastrectomyGastroscopyNeuroendocrine TumorsStomach NeoplasmsEndosonographyHumansPrognosisRisk FactorsEndoscopic full-thickness resectionEndoscopic mucosal resectionEndoscopic submucosal dissectionPrognostic markerRisk factors

Identifiers

PMID42228075

DOI10.1007/s00104-026-02511-3

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.